$BIIB · BIOGEN INC.
Biogen reported Q3 2026 results with total revenue of $2.804B, up 11% YoY. GAAP diluted EPS swung to a loss of $(0.14) from $3.17 a year ago, driven by a $284M acquired IPR&D charge primarily from the RayThera acquisition. Non-GAAP diluted EPS was $2.62, down 46% from $4.81. The company raised the low end of its FY 2026 Non-GAAP EPS guidance to $12.20-$13.00 from $12.00-$13.00.
- Total revenue of $2.804B grew 11% YoY (10% constant currency), driven by 49% Growth Portfolio expansion to $1.26B.
- GAAP diluted EPS swung to $(0.14) from $3.17, crushed by $284M acquired IPR&D charge primarily from the RayThera acquisition.
- Non-GAAP diluted EPS fell 46% YoY to $2.62 from $4.81, also absorbing the same $284M IPR&D expense.
- Full-year 2026 Non-GAAP EPS guidance raised at the low end to $12.20-$13.00 (from $12.00-$13.00), reflecting Apellis dilution favorability.
- Multiple Phase 3 readouts expected within 12 months: litifilimab (TOPAZ-1/2) in December 2026, felzartamab and zorevunersen in 2027.
Extended-hours trading shows BIIB at $259.75, +2.78% vs the regular close of $252.73, suggesting the market is rewarding the revenue beat and guidance raise despite the GAAP loss and Non-GAAP EPS decline.
Biogen's return to double-digit revenue growth is overshadowed by a massive IPR&D charge that flipped GAAP EPS negative, but the guidance raise and near-term Phase 3 catalysts give investors a clear risk/reward setup.
Biogen's Growth Portfolio pivot is gaining traction with 49% YoY expansion, but the heavy reliance on M&A (Apellis, RayThera) and IPR&D charges mirrors the broader biopharma playbook of buying growth to offset legacy franchise erosion.
The $284M acquired IPR&D charge from the RayThera acquisition drove GAAP EPS to a loss and cut Non-GAAP EPS nearly in half YoY. MS product revenue continues to erode (-13% YoY to $919M), and the Apellis integration adds execution risk alongside $7.7B in total debt.